Top of this page
Skip navigation, go straight to the content

 

Olokizumab

Disease area
studied
Abbreviated title Phase Study ID Registry database Study results Lay summary Publication (if available)
Crohn's Disease A Phase II Study to Assess the Efficacy and Safety of Olokizumab in Patients With Crohn's Disease Phase 2 CD0001
Terminated
NCT01635621
2011-002517-11
Rheumatoid Arthritis Efficacy and Safety of CDP6038 in Patients With Rheumatoid Arthritis With an Unsuccessful Response to Anti-Tumor Necrosis Factor (Anti-TNF) Therapy Phase 2 RA0056
Completed
NCT01242488
2010-020839-39
Genovese, M. C. et al. Ann Rheum Dis;2014;73;9;1607-1615
Rheumatoid Arthritis Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056 Phase 2 RA0057
Completed
NCT01296711
2010-022224-77
Rheumatoid Arthritis Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy Phase 2 RA0083
Completed
NCT01463059 Takeuchi, T.et al. Mod Rheumatol;9-10-2015;1-9
Rheumatoid Arthritis The Long-term Safety and Efficacy of Olokizumab (CDP6038) With Active Rheumatoid Arthritis Phase 2 RA0089
Completed
NCT01533714